A diary of the thought process behind my investment decisions
Lilly Beats And Raises
Eli Lilly beat profit estimates and raised guidance. Pfizer did the same yesterday but the stock fell flat. I believe Eli Lilly has a better chance of rallying even though it has already had a nice run, as it is the most hated pharmaceutical stock. Goldman Sachs has it on its Conviction Sell List. When a stock is hated and does well, there is a lot of upside potential. Eli Lilly is my second largest holding, next to Pfizer.